Hepatic steatosis: An experimental model for quantification

Archives of Gerontology and Geriatrics

Volumn 52, Issue 2, 2011, Pages 164-166

  Wu, Tzee Chung ^a,b   Chen, Liang Kung ^a,b   Tsai, Shyh Hao ^a,b   Liaw, Yi Hsin ^a   Hwang, Betau ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bioelectric impedance; Fatty liver; Hepatic steatosis; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOELECTRIC IMPEDANCE ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; FATTY LIVER; HISTOPATHOLOGY; IMPEDANCE; LIVER WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ALANINE TRANSAMINASE; ANIMALS; BIOPSY; BODY WEIGHT; ELECTRIC IMPEDANCE; FATTY LIVER; LIPIDS; MALE; MODELS, BIOLOGICAL; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX;

RATTUS;

EID: 79551595787     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2010.03.009     Document Type: Article

References (12)

1. Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver disease. Can. Med. Assoc. J. 2005, 172:899-905.
2. Bellentani S., Saccoccio G., Masutti F., Crocè L.S., Brandi G., Sasso F., Cristanini G., Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132:112-117.
3. Cairns S.R., Peters T.J. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin. Sci. 1983, 65:645-652.
4. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., Driscoll C.J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
5. Clark J.M., Diehl A.M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. J. Am. Med. Assoc. 2003, 289:3000-3004.
6. Koteish A., Diehl A.M. Animal models of heaptosteatosis. Best Pract. Res. Clin. Gastroenterol. 2002, 16:679-690.
7. Kyle, U.G., Bosaeus, I., De Lorenzo, A.D., Deurenberg, P., Elia, M., Manuel Gómez, J., Lilienthal Heitmann, B., Kent-Smith, L., Melchior, J.C., Pirlich, M., Scharfetter, H., Schols, M.W.J., Pichard, C., The ESPEN Working Group. 2004. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin. Nutr. 23, 1430-1453.
8. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
9. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
10. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
11. Nonomura A., Mizukami Y., Unoura M., Kobayashi K., Takeda Y., Takeda R. Clinicopathologic study of alcohol-like liver disease in nonalcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol. Jpn. 1992, 27:521-528.
12. Teli M., James O.F., Burt A.D., Bennett M.K., Day C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.